Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 6/2003

01-03-2003 | Therapy In Practice

Fixed-Dose Combination Drugs for Tuberculosis

Application in Standardised Treatment Regimens

Authors: Dr Bjørn Blomberg, Bernard Fourie

Published in: Drugs | Issue 6/2003

Login to get access

Abstract

Short-course chemotherapy is highly efficacious in treating tuberculosis (TB). However, the length (≥6 months) and complexity (three or four different drugs) of the treatment makes adherence difficult. Erratic treatment not only fails to cure patients but also creates chronically contagious cases, who may excrete drug-resistant TB bacteria. The Directly Observed Treatment Short-course (DOTS) strategy recommended by WHO provides a comprehensive organisational and infrastructural framework for the rational use of diagnosis, drug supply, as well as case and programme management services, in TB control. WHO and other organisations recommend fixed-dose combination formulations (FDCs) as a further step to facilitate the optimal drug treatment of TB. Using FDCs in TB control will simplify the doctor’s prescription and patient’s drug intake, as well as the drug supply management of the programme. By preventing monotherapy and facilitating the ingestion of adequate doses of the constituent anti-TB drugs, FDCs are expected to help prevent the emergence of drug resistance.
This article presents the international recommendations for the use of FDCs in TB programmes. The fundamental issue is to obtain drug supplies of good quality. A laboratory network for quality testing, including bioavailability testing of FDCs exists, and the recently established Global TB Drug Facility (GDF) supplies quality TB drugs, including 4-drug FDCs, to countries requesting assistance. This articles deals with the requirements for a successful transition to FDC-based treatment. It emphasises the need for appropriately revised programme documentation (programme manual, training modules, treatment guidelines and forms), training of staff at all levels, carefully calculated drug needs, and a plan for the exhaustion of existing stocks of loose tablets and the phasing-in of FDCs at all levels of the programme at the same time. Loose drugs for individualised treatment of patients with adverse effects should be kept at district or central health institutions.
Literature
1.
Reichman LB. Tuberculosis elimination: what’s to stop us? Int J Tuberc Lung Dis 1997; 1(1): 3–11PubMed
2.
Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333(4): 229–33PubMedCrossRef
3.
Pablos-Mendez A, Laszlo A, Bustreo F, et al. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 1994–1997. Geneva: World Health Organization, 1997. Report No.: WHO/TB/97.229. Available from URL: http://​www.​who.​int/​gtb/​publications/​dritw/​index.​htm [Accessed 2002 Aug 14]
4.
Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338(23): 1641–9PubMedCrossRef
5.
Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999; 58(4): 633–61PubMedCrossRef
6.
7.
8.
Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344(17): 1294–303PubMedCrossRef
9.
Dye C, Espinal MA, Watt CJ, et al. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185(8): 1197–202PubMedCrossRef
10.
Dye C, Williams BG, Espinal MA, et al. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295(5562): 2042–6PubMedCrossRef
11.
Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73(6): 311–21PubMedCrossRef
12.
De Cock KM, Soro B, Coulibaly IM, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992; 268(12): 1581–7PubMedCrossRef
13.
14.
15.
Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282(7): 677–86PubMedCrossRef
16.
17.
World Health Organization, International Union Against Tuberculosis and Lung Disease. The promise and reality of fixed-dose combinations with rifampicin: a joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994; 75(3): 180–1
18.
World Health Organization, International Union Against Tuberculosis and Lung Disease. Assuring bioavailability of fixed-dose combinations of antituberculosis medication: a joint statement of the International Union Against Tuberculosis and Lung Disease and the World Health Organization. Int J Tuberc Lung Dis 1999; 3 (11 Suppl.): S282–3
19.
Blomberg B, Spinaci S, Fourie B, et al. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis [online]. Available from URL: http://​www.​who.​int/​bulletin/​pdf/​2001/​issuel/​bu0435.​pdf [Accessed 2003 Jan 31]. Bull World Health Organ 2001; 79(1): 61–8PubMed
20.
Essential drugs. WHO Model List (revised December 1999). WHO Drug Information 1999; 13(4): 249–62
21.
22.
USP 25-NF 20, 2002. The Official Compendia of Standards. United States Pharmacopeia, 25th Revision; National Formulary, 20th Revision. 1st Supplement to USP 25-NF 20. Rock-ville (MD): The United States Pharmacopeial Convention Inc., 2002
23.
Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65(1): 6–24PubMed
24.
Andvord KF. What can we learn by following the development of tuberculosis from one generation to another?. 1930 [classical article]. Int J Tuberc Lung Dis 2002; 6(7): 562–8PubMed
25.
Uplekar MW, Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72(4): 284–90PubMedCrossRef
26.
Sumartojo E, Hale B, Geiter L. Physician practices in preventing and treating tuberculosis: results of a national survey. Am Rev Respir Dis 1993; 147: A702
27.
Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948; I: 582–96
28.
Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2: 769–82CrossRef
29.
Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966; 47: 381–93CrossRef
30.
Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1960; 23: 535–85
31.
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (10 Suppl. 2): S231–79PubMed
32.
Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization [editorial]. Tubercle 1991; 72(1): 1–6PubMedCrossRef
33.
Rouillon A. Problems raised by the organization of an efficient ambulatory treatment for tuberculous patients: motivation. Bull Int Union Tuberc 1972; 47: 72–87
34.
Sbarbaro J, Blomberg B, Chaulet P. Fixed-dose combination formulations for tuberculosis treatment. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S286–8PubMed
35.
Norval PY, Blomberg B, Kitler ME, et al. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S292–300; discussion S317-21PubMed
36.
Blomberg B, Evans P, Phanouvong S, et al. Informal consultation on 4-drug fixed-dose combinations compliant with the WHO Model List of Essential Drugs. Geneva, Switzerland, 15–17 August 2001. Geneva: UNDP, World Bank, WHO Special Programme for Research & Training in Tropical Diseases (TDR); 2002. Report No.: TDR/TB/02.1, WHO/CDS/TB/ 2002.99. Available from URL: http://​www.​who.​int/​tdr/​publications/​publications/​4fdc.​htm [Accessed 2002 Dec 10]
37.
38.
39.
Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann Intern Med 1990; 112(6): 397–406PubMed
40.
Geiter LJ, O’Brien RJ, Combs DL, et al. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987; 68 (2 Suppl.): 41–6PubMedCrossRef
41.
Chaulet P, Boulahbal F. Essai clinique d’une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis]. Groupe de Travail sur la Chimiotherapie de la Tuberculose. Tuber Lung Dis 1995; 76(5): 407–12PubMedCrossRef
42.
Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly anti-tuberculosis chemotherapy. Am Rev Respir Dis 1989; 140(6): 1618–22CrossRef
43.
Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143 (4 Pt 1): 700–6
44.
Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143 (4 Pt 1): 707–12
45.
Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3(2): 126–32PubMed
46.
Iseman MD. Good news and not such good news. Int J Tuberc Lung Dis 1999; 3(2): 87PubMed
47.
Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976; 19 (5 Pt 2): 610–25PubMed
48.
Parrot R, Boval C, Grosset J, et al. Adjusting or not adjusting isoniazid dosage? Rev Fr Mal Respir 1983; 11(5): 705–12PubMed
49.
Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51(2): 132–6PubMedCrossRef
50.
Laing RO, McGoldrick KM. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 2000; 4 (12 Suppl. 2): S194–207PubMed
51.
Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2(1): 10–5PubMed
52.
Snider DE, Graczyk J, Bek E, et al. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130(6): 1091–4PubMed
53.
Girling DJ. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. Tubercle 1984; 65: 1–4PubMedCrossRef
54.
East African and British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: first report of 4th study. Lancet 1978; II(8085): 334–8
55.
Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119(4): 579–85
56.
British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. Br J Dis Chest 1981; 75(2): 141–53CrossRef
57.
Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can’t afford not to try it. N Engl J Med 1993; 328(8): 576–8PubMedCrossRef
58.
Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270(1): 65–8PubMedCrossRef
59.
Weyer K, Fourie PB, Nardell EA. The global impact of drug-resistant tuberculosis: Chapter 5. A noxious synergy: tuberculosis and HIV in South Africa. Boston (MA): Harvard Medical School and Open Society Institute, 1999
60.
Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8(4): 496–514PubMed
61.
62.
David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20(5): 810–4PubMed
63.
David HL. Drug-resistance in M. tuberculosis and other mycobacteria. Clin Chest Med 1980; 1(2): 227–30PubMed
64.
Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330(17): 1179–84PubMedCrossRef
65.
Weyer K, Groenewald P, Zwarenstein M, et al. Tuberculosis drug resistance in the Western Cape. S Afr Med J 1995; 85(6): 499–504PubMed
66.
Laing R, Fourie B, Ellard G, et al. World Health Organization.b Fixed dose combination tablets for the treatment of tuberculosis. Report from an informal meeting held in Geneva, Tuesday 27 April 1999. Geneva: World Health Organization, 1999. Report No.: WHO/CDS/CPC/TB/99.267. Available from URL: http://​www.​who.​int/​gtb/​publications/​fdc/​index.​htm [Accessed 2002 Aug 14]
67.
Taylor RB, Shakoor O, Behrens RH. Drug quality: a contributor to drug resistance [letter]? Lancet 1995; 346(8967): 122PubMedCrossRef
68.
Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997; 2(9): 839–45PubMedCrossRef
69.
O’Brien KL, Selanikio JD, Hecdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning: Acute Renal Failure Investigation Team. JAMA 1998; 279(15): 1175–80PubMedCrossRef
70.
Pillai G, Fourie PB, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S309–16, discussion S317-21PubMed
71.
Schofield J. Counterfeit Pharmaceuticals flood Russian market [letter]. BMJ 2001; 322(7302): 1564dCrossRef
72.
Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001; 357(9272): 1933–6PubMedCrossRef
73.
Chatterjee P. India’s trade in fake drugs: bringing the counterfeiters to book [letter]. Lancet 2001; 357(9270): 1776PubMedCrossRef
74.
Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133(6): 1076–80PubMed
75.
Acocella G, Nonis A, Gialdroni-Grassi G, et al. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. Am Rev Respir Dis 1988; 138(4): 882–5PubMedCrossRef
76.
Acocella G, Nonis A, Perna G, et al. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am Rev Respir Dis 1988; 138(4): 886–90PubMedCrossRef
77.
Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64(1): 38–40PubMed
78.
Fox W. Tuberculosis in India, past, present and future. Ind J Tub 1990; 37: 175–213
79.
80.
Schall R, Muller FO, Duursema L, et al. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. Arzneimittel Forschung 1995; 45(11): 1236–9
81.
Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. Int J Tuberc Lung Dis 1998; 2(10): 824–30PubMed
82.
Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3(11 Suppl. 3): S301–8, discussion S317-21PubMed
83.
Mcllleron H, Wash P, Burger A, et al. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6(4): 356–61
84.
BlombergB, Kitler ME, Milstien J, et al. Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization’s vaccine model? Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S371–80, discussion S381-7
85.
Fourie PB, Pillai C, Mcllleron H, et al. Model Protocol: establishing the bioequivalence of rifampicin in fixed-dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administeed in loose combination. Geneva: World Health Organization, 1999. Report No.: Unpublished document WHO/CDS/TB/99.274
86.
Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers. Int J Tuberc Lung Dis 1999; 3(11): S284–5
87.
Fourie PB, Spinaci S. Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S368–70, discussion S381-7PubMed
88.
Ellard GA. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S322–4, discussion S351-2PubMed
89.
Allen KA, Fourie TG, von Gruenewaldt KG, et al. New four-drug fixed-dose combination for treatment of tuberculosis [abstract]. Int J Tuberc Lung Dis 1999; 3: S50
90.
Fourie PB, van Niekerk CH, Smith P, et al. Bioavailability study comparing a four-drug fixed-dose combination tablet, rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400mg and ethambutol 275mg (Rifafour e-275), to equivalent doses of reference drugs. Int J Tuberc Lung Dis 1999; 3 (9 Suppl. 1): S49–50
91.
Arnadottir T, Rieder HL, Enarson DA. Tuberculosis programs. Review, planning, technical support: a manual of methods and procedures. Paris: Internatioinal Union Against Tuberculosis and Lung Disease (IUATLD), 1998. Available from URL: http://​www.​iuatld.​org/​html/​body_​guides.​htm [Accessed 2002 Aug 14]
Metadata
Title
Fixed-Dose Combination Drugs for Tuberculosis
Application in Standardised Treatment Regimens
Authors
Dr Bjørn Blomberg
Bernard Fourie
Publication date
01-03-2003
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363060-00002

Other articles of this Issue 6/2003

Drugs 6/2003 Go to the issue

Therapy In Practice

Barrett’s Oesophagus

Review Article

Blood Coagulation in Patients with Chronic Heart Failure

Current Opinion

Nonsteroidal Anti-Inflammatory Drugs and Heart Failure

Adis Drug Evaluation

Atovaquone/Proguanil

Review Article

Hyperphosphataemia in Renal Failures